This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BridgeBio Pharma (BBIO) Moves 14.6% Higher: Will This Strength Last?
by Zacks Equity Research
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Biotech Stock Roundup: Regulatory Updates From NVAX, BBIO Down on Drug Failure & More
by Zacks Equity Research
Regulatory and other pipeline updates from NVAX and BBIO are among a few key highlights from the biotech sector during the past week.
Company News for Dec 28, 2021
by Zacks Equity Research
Companies in The News Are: GDDY,BBIO,UAL,MBOTSYK
BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure
by Zacks Equity Research
BridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend. The study continues.
Implied Volatility Surging for BridgeBio (BBIO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BridgeBio (BBIO) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in BridgeBio (BBIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to BridgeBio (BBIO) stock based on the movements in the options market lately.
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -16.48% and -87.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 29.03% and 7.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -35.63% and -95.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season?
by Zacks Equity Research
BridgeBio Pharma (BBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -17.44% and -99.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.03% and -52.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: BridgeBio Pharma (BBIO) Q3 Earnings Expected to Decline
by Zacks Equity Research
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion Plans to Raise 2020 Sales View, Buy Back $3B Shares
by Zacks Equity Research
Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.
Why BridgeBio (BBIO) Stock Might be a Great Pick
by Zacks Equity Research
BridgeBio (BBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%
by Zacks Equity Research
BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan
by Zacks Equity Research
Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.